item management s discussion and analysis of financial condition and results of operations liquidity and capital resources the company has cash and cash equivalents of approximately million and working capital of approximately million at march  the company generated approximately  of cash from operations during the fiscal year ended march  the increase in funds generated comes from net income  the decrease in inventory levels and prepaid expenses offset by a decrease in accounts payable and accrued expenses 
during fiscal year  approximately  was used in investing activities chiefly for the purchase of fixed assets 
approximately  was used in financing activities 
the funds were used to purchase treasury stock and to pay down long term debt and offset by the increase in short term borrowings 
in april  the company entered a new relationship with a major dutch bank  which provides for a  dutch guilder approximately  line of credit 
interest on this facility is set at above the base rate as reported by the netherlands central bank  presently 
trade receivables and inventory of vital scientific are provided as security for this facility 
the line continues as long as certain capital covenants are met 
as of march   the company is in full compliance with all capital covenants of the credit line and no amounts are outstanding 
in may  clinical data australia entered into an agreement for a  australian dollar approximately  line of credit with an australian bank 
interest on this facility is set at prime plus  the prime rate is presently 
trade receivables and inventory of clinical data australia are provided as security for this facility  the line also requires the maintenance of certain capital ratios 
as of march   the company is in full compliance with all capital covenants of the credit line and no amounts are outstanding 
the company s sources of cash include cash balances and the aforementioned lines of credit from dutch and australian banks 
the company believes that available funds will provide it with sufficient working capital through fiscal year the effect of foreign currency transaction exchange on the results of operations is included in other income expense and is not material to the financial statements 
see note in notes to the consolidated financial statements 
any impact on the company s liquidity is largely dependent on the exchange rates in effect at the time the company s predominant foreign functional currency  the dutch guilder  is translated into us dollars 
approximately  of the march  balance of  of cash and cash equivalents is denominated in us dollars 
the effect of translation into us dollars of the amounts held in local currencies is reflected as a separate component of stockholders investment on the balance sheet 
the cumulative translation adjustment in stockholders investment is approximately of total assets on the march  consolidated balance sheet 
the effects of currency exchange rates on future quarterly or fiscal periods on the results of operations are difficult to estimate 
there are no formal hedging procedures employed by the company 
the primary risk is to monetary assets and liabilities denominated in currencies other than the us dollar 
approximately million of million of current assets reside in the company s foreign subsidiaries 
results of operations forward looking statements  within the meaning of the securities exchange act of section e  may be made throughout this discussion and analysis 
for this purpose  any statements contained herein that are not statements of historical fact may be deemed to be forward looking statements 
without limiting the foregoing  such words as  anticipates  plans  expects  believes  estimates  and similar expressions are intended to identify such forward looking statements 
such statements involve risk and uncertainties  including but not limited to competitive  governmental  economic  and technological factors that may affect the company s operations  products  markets  and services 
actual results could differ materially from those expressed in such statements and readers are referred to the company s other sec reports and filings 
fiscal year ended march  compared to fiscal year ended march  when analyzing the comparative revenue and expense figures presented below for the fiscal years ended march  and  consideration should be given to the weakening of the company s functional currency  the dutch guilder  against the united states dollar 
consolidated revenues for fiscal year decreased as compared to fiscal year revenues  when expressed in the company s functional currency  the dutch guilder  were approximately the same as in fiscal year as expressed in dutch guilders  sales at vital scientific decreased between years because of lower unit sales of certain products 
this was offset by an increase in sales at clinical data australia of when expressed in australian dollars and impacted by a decrease of in revenues at novachem 
the gross margin increased from for the year ended march  to for the year ended march  the increased margin is the consolidated result of improved performance at each of the operating subsidiaries as a result of improved product pricing  reduced product costs  and the effect of a sponsored research and development contract 
sales and marketing expenses decreased on a consolidated basis as compared to the prior year 
the decrease is primarily the result of a cost containment program at vital scientific and novachem offset by an increase in sales expenses at clinical data australia commensurate with their increase in revenues 
research and development expenses increased as compared to fiscal year this increase is principally due to the aforementioned sponsored research and development contract at vital scientific 
general and administrative expenses decreased from last year 
during the fourth quarter of fiscal year  the company began implementation of a restructuring plan at the company s subsidiary  vital scientific 
as of march   the restructuring plan was completed and all amounts charged against the profit and loss statements have been paid out 
interest expense decreased from fiscal year the decrease is principally due to fewer unit sales of the hytec that was financed under a governmental development subsidy 
this loan is repaid as units of the product are sold 
interest income decreased  as fewer funds were available during the year for investment 
other income and expense in fiscal year results principally from an adjustment for interest in a subsidy 
in fiscal year the amount for other income and expense was principally due to the effect of foreign currency transaction gains and losses on the results of operations 
the minority interest as shown on the fiscal year financial statements is the of clinical data australia sold to an officer of the company on may  the details of this transaction are disclosed in note in the notes to consolidated financial statements 
in fiscal year  the minority interest was attributable to the of vital scientific that was not owned by the company 
on october   vital scientific became a wholly owned subsidiary 
fiscal year ended march  compared to fiscal year ended march  consolidated revenues for fiscal year were  versus  for fiscal year  an increase of approximately 
the increase is due to an aggregate increase in sales at each of the company s operating subsidiaries coupled with a strengthening of the company s primary functional currency  the dutch guilder  against the united states dollar 
for the entire year  the gross margin declined from in fiscal year to in fiscal year the decrease principally results from competitive pricing pressure combined with a product mix of instruments with lower margins 
sales and marketing expenses increased  or from fiscal year  of the increase is because of a one time release of certain reserves during fiscal year related to the settlement of a dispute with a customer that is described in note to the consolidated financial statements 
the remainder is primarily attributable to expenses associated with the training of new distributors and a new product introduction 
research and development expenses  as shown on the fiscal year consolidated statements of operations  increased  or from fiscal year during fiscal years and  the company spent an additional  and  respectively  which were capitalized onto the balance sheet pursuant to the precepts of statement of financial accounting standards no 
see note m in the notes to the consolidated financial statements 
the overall increase in research and development expenses is  therefore   or when compared to the prior year 
this increase in r d expense is primarily related to new product concept and development activities 
general and administrative expenses increased  or from fiscal year the increase is primarily due to exchange rate fluctuations 
in the fourth quarter of fiscal  the company began implementation of a restructuring plan at its vital scientific subsidiary 
as of march   the company had terminated three employees  one in sales and two in research and development and planned to complete the restructuring in the first half of fiscal year management anticipated the future amount of the restructuring charge to approximate  at march   the entire amount of the accrual remained and was comprised entirely of severance related costs 
the total cash impact of the restructuring related to fiscal year was  which was paid during fiscal year interest expense increased primarily from expenses related to the credit financing grant received by vital scientific from the dutch government for new product development 
the grant is repaid from product sales with interest accruing on the unpaid balance 
interest income decreased from fiscal year because funds were used to payoff the deficit balance in cash at the company s former bank before opening a relationship with a new bank 
for fiscal year  other income and expense  as illustrated in note in the notes to consolidated financial statements  is largely comprised of foreign currency transaction gains and losses on the results of operations 
in fiscal year  the account was predominantly consisted of the gains from the settlement of a dispute with a customer and from the sale of certain assets at vital scientific 
item a 
quantitative and qualitative disclosure about market risk foreign exchange the accounts of the company s foreign subsidiaries are translated in accordance with sfas no 
 foreign currency translation 
in translating the accounts of the foreign subsidiaries into us dollars  assets and liabilities are translated at the rate of exchange in effect at year end  while stockholders equity is translated at historical rates 
revenue and expense accounts are translated using the weighted average exchange rate in effect during the year 
gains and losses from translating assets and liabilities that are denominated in currencies other than the subsidiaries respective functional currency are included in other expense in the consolidated statements of operations 
the translation adjustment required to report those subsidiaries whose functional currency is other than the united states dollar into us dollars is credited or charged to cumulative translation adjustment  included as a separate component of stockholders investment in the accompanying consolidated balance sheets 
substantially all of the company s sales were denominated in foreign currencies during fiscal the company recognized a loss of approximately  related to such foreign currency transactions and translations in which is included in cumulative translation adjustment in the accompanying consolidated statements of stockholders investment 
investment portfolio the company does not invest in derivative financial instruments that meet the high quality standards  as specified in the company s investment policy guidelines  the policy also limits the amount of credit exposure of any issue  issuer  and type of investment 
see note summary of significant accounting policies in the notes to consolidated financial statements 

